The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial
Open accessAbstract
BACKGROUND: Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response. OBJECTIVE: The purpose of this study was to analyze disease-free and overall survival. DESIGN: This was a nonrandomized phase II trial. SETTINGS: The study was conducted at multiple institutions. PATIENTS: Four sequential study groups with stage II or III rectal cancer were included. INTERVENTION: All of the patients received 50 Gy of radiation with concurrent continuous infusion of fluorouracil for 5 weeks. Patients in each group received 0, 2, 4, or 6 cycles of modified FOLFOX6 after chemoradiation and before total mesorectal excision. Patients were recommended to receive adjuvant chemotherapy after surgery to complete a total of 8 cycles of modified FOLFOX6. MAIN OUTCOME MEASURES: The trial was powered to detect differences in pathological complete response, which was reported previously. Disease-free and overall survival are the main outcomes for the current study. RESULTS: Of 259 patients, 211 had a complete follow-up. Median follow-up was 59 months (range, 9–125 mo). The mean number of total chemotherapy cycles differed among the 4 groups (p = 0.002), because one third of patients in the group assigned to no preoperative FOLFOX did not receive any adjuvant chemotherapy. Disease-free survival was significantly associated with study group, ypTNM stage, and pathological complete response (p = 0.004, <0.001, and 0.001). A secondary analysis including only patients who received ≥1 cycle of FOLFOX still showed differences in survival between study groups (p = 0.03). LIMITATIONS: The trial was not randomized and was not powered to show differences in survival. Survival data were not available for 19% of the patients. CONCLUSIONS: Adding modified FOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer. Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. See Video Abstract at http://links.lww.com/DCR/A739.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Mesorectal excision for rectal cancer
MacFarlane, J. K., Ryall, R. D. H., & Heald, R. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90207-w · Cited by 1,781
Cited by
Bahadoer, R. R., Dijkstra, E. A., van Etten, B., Marijnen, C. A. M., Putter, H., Kranenbarg, E. M.-K., Roodvoets, A. G. H., Nagtegaal, I. D., Beets-Tan, R. G. H., Blomqvist, L. K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30555-6 · Cited by 1,693
Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G. G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.-L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00308 · Cited by 549
Petrelli, F., Trevisan, F., Cabiddu, M., Sgroi, G., Bruschieri, L., Rausa, E., Ghidini, M., & Turati, L. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003471 · Cited by 395
You, Y. N., Hardiman, K. M., Bafford, A., Poylin, V., Francone, T. D., Davis, K., Paquette, I. M., Steele, S. R., & Feingold, D. L. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001762 · Cited by 354
Metadata
- Authors
- Marco, M. R., Zhou, L., Patil, S., Marcet, J. E., Varma, M. G., Oommen, S., Cataldo, P. A., Hunt, S. R., Kumar, A., Herzig, D. O., Fichera, A., Polite, B. N., Hyman, N. H., Ternent, C. A., Stamos, M. J., Pigazzi, A., Dietz, D., Yakunina, Y., Pelossof, R., & Garcia-Aguilar, J.
- Venue
- Diseases of the Colon & Rectum
- Published
- 2018-10
- Volume
- 61
- Issue
- 10
- Pages
- 1146-1155
- ISSN
- 0012-3706 (ISSN-L)
- OpenAlex
- W2891131325
- Cited by
- 159
- References
- 2
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. https://app.cochat.ai/papers/10.1097/dcr.0000000000001207
- The paper
- Marco, M. R., Zhou, L., Patil, S., Marcet, J. E., Varma, M. G., Oommen, S., Cataldo, P. A., Hunt, S. R., Kumar, A., Herzig, D. O., Fichera, A., Polite, B. N., Hyman, N. H., Ternent, C. A., Stamos, M. J., Pigazzi, A., Dietz, D., Yakunina, Y., Pelossof, R., & Garcia-Aguilar, J. (2018). Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Diseases of the Colon & Rectum. https://doi.org/10.1097/dcr.0000000000001207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.